Eli Lilly

Early breast cancer patients in England will be able to access a new form of treatment following the recommendation for Eli Lilly’s abemaciclib by the National Institute of Health and Care Excellence (NICE).  The approval means that abemaciclib will be able to be used in combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative, […]

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   Abemaciclib will now be able to be used in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human […]